Seattle Genetics, Inc. (NASDAQ:SGEN) went down by -0.74% from its latest closing price when compared to the 1-year high value of $175.64 and move down -6.86%, while SGEN stocks collected -3.83% of loss with the last five trading sessions. Press Release reported 8 hours ago that Seattle Genetics Announces Positive Topline Results from Phase 2 Clinical Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer
Seattle Genetics, Inc. (NASDAQ:SGEN) Worth an Investment?
Seattle Genetics, Inc. (NASDAQ: SGEN) The 36 Months beta value for SGEN stocks is at 1.45, while of the analysts out of 0 who provided ratings for Seattle Genetics, Inc. stocks as a “buy” while as overweight, rated it as hold and as sell. The average price we get from analysts is $166.19 which is -$6.25 below current price. SGEN currently has a short float of 2.68% and public float of 171.83M with average trading volume of 1.30M shares.
SGEN Market Performance
SGEN stocks went down by -3.83% for the week, with the monthly jump of 4.55% and a quarterly performance of 42.57%, while its annual performance rate touched 137.49%. The simple moving average for the period of the last 20 days is 3.67% for SGEN stocks with the simple moving average of 38.85% for the last 200 days.
Analysts’ Opinion on Seattle Genetics, Inc. (NASDAQ:SGEN)
Many brokerage firms have already submitted their reports for SGEN stocks, with JMP Securities repeating the rating for SGEN shares by setting it to “Mkt Outperform”. The predicted price for SGEN socks in the upcoming period according to JMP Securities is $185 based on the research report published on May 26, 2020.
Guggenheim, on the other hand, stated in their research note that they expect to see SGEN stock at the price of $185. The rating they have provided for SGEN stocks is “Buy” according to the report published on May 1, 2020.
Needham gave “Buy” rating to SGEN stocks, setting the target price at $163 in the report published on May 1, 2020.
SGEN Stocks 6.34% Far from 50 Day Moving Average
After a stumble in the market that brought SGEN to its low price for the period of the last 52 weeks, Seattle Genetics, Inc. was unable to take a rebound, for now settling with -6.42% of loss for the given period.
The stock volatility was left at 3.83%, however, within the period of a single month, the volatility rate increased by 3.32%, while the shares surge at the distance of +3.36% for the moving average in the last 20 days. In oppose to the moving average for the last 50 days, trading by +20.09% upper at the present time.
In the course of the last 5 trading sessions, SGEN went down by -3.83%, which changed the moving average for the period of 200 days to the total of +131.90% of gains for the stock in comparison to the 20-day moving average settled at $158.81. In addition, Seattle Genetics, Inc. saw 43.86% in overturn over the period of a single year with a tendency to cut further gains.
SGEN Stock Insider Trading
Reports are indicating that there were more than several insider trading activities at Seattle Genetics, Inc. (SGEN), starting from LIU JEAN I, who sold 9,877 shares at the price of $165.00 back on Jun 19. After this action, Rushing now owns 63,597 shares of Seattle Genetics, Inc., valued at $1,629,705 with the latest closing price.
DANSEY ROGER D, the Chief Medical Officer of Seattle Genetics, Inc., sold 2,162 shares at the value of $158.89 during a trade that took place back on Jun 17, which means that DANSEY ROGER D is holding 109,608 shares at the value of $343,523 based on the most recent closing price.
SGEN Stock Fundamentals
The current profitability levels are settled at -24.06 for the present operating margin and +95.21 for gross margin. The net margin for Seattle Genetics, Inc. stands at -17.31. Total capital return value is set at -13.67, while invested capital returns managed to touch -9.86. Equity return holds the value -18.70%, with -15.80% for asset returns.
Based on Seattle Genetics, Inc. (SGEN), the company’s capital structure generated 4.11 points for debt to equity in total, while total debt to capital is set at the value of 3.94.
The value for Enterprise to Sales is 19.83 with debt to enterprise value settled at 0.00. The receivables turnover for Seattle Genetics, Inc. is 4.80 with the total asset turnover at the value of 0.49. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.54.
An article written by Daisy Galbraith on newsheater.com